[Impact of dapagliflozin on cardiovascular risk factors. Beyond glycemic control]

Abstract

Sodium-glucose transport protein 2 (SGLT2) inhibitors are a new class of oral hypoglycemic agents that increase urinary glucose excretion independently of insulin secretion, although an apparently simple mechanism, but with multiple metabolic effects. Dapagliflozin was the first SGLT2 inhibitor marketed in Europe in 2012 for the treatment of patients with type 2 diabetes, and consequently, with the greatest clinical experience. The results of different clinical trials and real-life studies have demonstrated its effectiveness in glycemic control, as they reduce glycosylated hemoglobin, while achieving a decrease in body weight and blood pressure, among others, providing a comprehensive metabolic protection.

Keywords: Blood pressure; Dapagliflozin; Dapagliflozina; Diabetes; Inhibidores SGLT2; Peso; Presión arterial; SGLT2 inhibitors; Weight.